Development and Validation of the Surgical Assessment and Healthcare (SAH) Index for Gastric Cancer Treatment Evaluation
NCT07180966 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 780
Last updated 2026-05-26
Summary
This study develops the Surgical Assessment and Healthcare (SAH) Index, a new tool to fairly evaluate gastric cancer surgery outcomes. Gastric cancer is a serious disease that often requires major surgery, but it can be difficult to compare how well different hospitals or surgeons perform because patients have different levels of risk before surgery.
The SAH Index will help solve this problem by creating a standardized way to account for patient risk factors when evaluating surgical results. The study analyzes data from 780 patients who had gastric cancer surgery in 2019, looking at factors like patient age, tumor characteristics, molecular markers, and surgical outcomes.
By combining clinical information (like patient health), pathological details (like tumor type), and molecular features (like genetic markers), the SAH Index will create risk categories that allow fair comparison of surgical outcomes. This tool could help hospitals improve their care, help patients and families understand their treatment options, and help doctors make better treatment decisions.
The study uses only existing medical records and does not involve any new treatments or procedures. The goal is to create a practical tool that can be used by hospitals and doctors to better evaluate and improve gastric cancer surgery outcomes.
Conditions
- Gastric Cancer (GC)
Sponsors & Collaborators
-
Ruijin Hospital
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-01-02
- Primary Completion
- 2025-07-28
- Completion
- 2025-07-28
Countries
- China
Study Locations
More Related Trials
-
Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric Cancer
NCT00202969 ·Status: COMPLETED ·Phase: PHASE3
-
Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
NCT05498766 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
QL1706 Combined With SOX Used in Theperioperative Treatment
NCT06766305 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery
NCT05468138 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Long-term Heart-specific Mortality in the Presence of Competing Risks Among Patients With Non-metastatic Gastric Adenocarcinoma Undergoing Resection and Chemotherapy
NCT04820569 ·Status: COMPLETED
-
Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy
NCT06597227 ·Status: RECRUITING ·Phase: NA
-
SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
NCT06266871 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Total Robotic Versus Robotic Assisted Distal Gastrectomy for Gastric Cancer
NCT04795063 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
SP Intravenous Chemotherapy Versus SP by HIPEC in Stage Ⅲ Patients After D2 Gastrectomy
NCT02396498 ·Status: UNKNOWN ·Phase: PHASE3
-
Robot-assisted D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
NCT05728606 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.
NCT05188209 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Chemotherapy Plus Surgery Versus Surgery First For Elderly Gastric Cancer Patients
NCT04677673 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
NCT07102901 ·Status: RECRUITING ·Phase: PHASE2
-
Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection
NCT01534546 ·Status: UNKNOWN ·Phase: PHASE3
-
Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer
NCT05149807 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer
NCT02764268 ·Status: COMPLETED ·Phase: NA
-
Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma
NCT05184946 ·Status: UNKNOWN ·Phase: PHASE2
-
Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy
NCT06895447 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety Study of a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma
NCT01552980 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer
NCT04062058 ·Status: UNKNOWN ·Phase: PHASE2
-
Real World Study of Immune Checkpoint Inhibitors for Advanced Gastric Cancer
NCT04086888 ·Status: UNKNOWN
-
Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery
NCT07149181 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
A Benefit Population Atlas of nICT Versus nCT for LAGC
NCT07098104 ·Status: COMPLETED
-
Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer
NCT01756183 ·Status: UNKNOWN ·Phase: PHASE2
-
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
NCT06504732 ·Status: RECRUITING ·Phase: PHASE2/PHASE3